Morgan Stanley lowered the firm’s price target on Exelixis (EXEL) to $44 from $50 and keeps an Overweight rating on the shares after company presented detailed STELLAR-303 data comparing zanzalintinib plus atezolizumab versus regorafenib in metastatic colorectal cancer. In mCRC, the firm lowers its patient market share assumption to 9% from 11% of the modeled incidence population and it maintain its “conservative” 40% odds of success assumption.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target lowered to $30 from $36 at Wells Fargo
- Leerink upgrades Exelixis to Outperform following ESMO presentation
- Exelixis upgraded to Outperform from Market Perform at Leerink
- Exelixis’s Zanzalintinib Shows Promise in Phase III Trial, Justifying Buy Rating Despite Safety Concerns
- Midday Fly By: AWS hit by outage, Kering sells beauty unit